ARTICLE | Company News
Takeda submits vedolizumab MAA
March 9, 2013 1:54 AM UTC
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an MAA to EMA for vedolizumab to treat moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). The pharma said it plans to...